Sarah Benafif

4.3k total citations
23 papers, 359 citations indexed

About

Sarah Benafif is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sarah Benafif has authored 23 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Sarah Benafif's work include Prostate Cancer Treatment and Research (5 papers), COVID-19 and healthcare impacts (4 papers) and Genetic Associations and Epidemiology (3 papers). Sarah Benafif is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), COVID-19 and healthcare impacts (4 papers) and Genetic Associations and Epidemiology (3 papers). Sarah Benafif collaborates with scholars based in United Kingdom, United States and Australia. Sarah Benafif's co-authors include Rosalind A. Eeles, Marcia Hall, Zsofia Kote‐Jarai, John Bridgewater, Paul J. Ross, Ángela Lamarca, Juan W. Valle, Diego Ottaviani, Ian Whitmore and Heather Shaw and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Urology.

In The Last Decade

Sarah Benafif

22 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Benafif United Kingdom 8 167 134 131 80 64 23 359
Deniz Yamaç Türkiye 13 113 0.7× 147 1.1× 211 1.6× 56 0.7× 83 1.3× 44 439
C Singer Austria 9 55 0.3× 93 0.7× 126 1.0× 85 1.1× 97 1.5× 15 314
Pedro Exman United States 8 126 0.8× 95 0.7× 255 1.9× 34 0.4× 100 1.6× 21 383
Erika Matos Slovenia 8 75 0.4× 105 0.8× 210 1.6× 33 0.4× 199 3.1× 27 409
Kenji Higaki Japan 11 98 0.6× 57 0.4× 200 1.5× 68 0.8× 159 2.5× 39 363
Valentina Sini Italy 13 93 0.6× 63 0.5× 242 1.8× 53 0.7× 106 1.7× 25 399
Carolyn Cullinane Ireland 10 78 0.5× 78 0.6× 188 1.4× 29 0.4× 163 2.5× 29 366
Ryan Geschwindt United States 10 137 0.8× 94 0.7× 80 0.6× 47 0.6× 37 0.6× 15 337
James P. De Andrade United States 12 100 0.6× 195 1.5× 134 1.0× 27 0.3× 85 1.3× 25 400
Zhi‐Gang Sun China 12 94 0.6× 155 1.2× 87 0.7× 15 0.2× 73 1.1× 46 369

Countries citing papers authored by Sarah Benafif

Since Specialization
Citations

This map shows the geographic impact of Sarah Benafif's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Benafif with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Benafif more than expected).

Fields of papers citing papers by Sarah Benafif

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Benafif. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Benafif. The network helps show where Sarah Benafif may publish in the future.

Co-authorship network of co-authors of Sarah Benafif

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Benafif. A scholar is included among the top collaborators of Sarah Benafif based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Benafif. Sarah Benafif is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heist, Rebecca S., Elaine Shum, Esther García Pagès, et al.. (2025). MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.. Journal of Clinical Oncology. 43(16_suppl). 8613–8613. 1 indexed citations
2.
3.
Venkatesan, Subramanian, Dionysis Papadatos-Pastos, Tanya Ahmad, et al.. (2024). Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report. JTO Clinical and Research Reports. 5(12). 100746–100746. 4 indexed citations
4.
Eeles, Rosalind A., Elizabeth Bancroft, Edward J. Saunders, et al.. (2024). Effect of polygenic risk score for clinically significant prostate cancer in a screening program: The BARCODE 1 study results.. Journal of Clinical Oncology. 42(16_suppl). 10500–10500. 3 indexed citations
5.
Awan, Sidra, et al.. (2023). Out-of-hours admissions in patients treated with immune checkpoint inhibitors and their primary management with steroids. Journal of Oncology Pharmacy Practice. 30(7). 1193–1199. 2 indexed citations
6.
7.
Wong, Yien Ning Sophia, Christopher C.T. Sng, Diego Ottaviani, et al.. (2021). Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital. Cancers. 13(23). 6085–6085. 2 indexed citations
8.
Benafif, Sarah, et al.. (2021). Genetics of prostate cancer and its utility in treatment and screening. Advances in genetics. 108. 147–199. 1 indexed citations
9.
Moore, David A., Sarah Benafif, Siow Ming Lee, et al.. (2021). Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer. Lung Cancer. 161. 55–59. 11 indexed citations
10.
Alifrangis, Constantine, Olivia Lucas, Sarah Benafif, et al.. (2020). Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery. European Urology Focus. 7(4). 835–842. 7 indexed citations
11.
Sng, Christopher C.T., Yien Ning Sophia Wong, Anjui Wu, et al.. (2020). Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience. Frontiers in Oncology. 10. 595804–595804. 17 indexed citations
12.
Soosaipillai, Gehan, Anna Sureda, Sarah Benafif, et al.. (2020). 1671MO Provision of palliative care for patients with cancer and SARS-CoV-2 infection. Annals of Oncology. 31. S992–S992. 2 indexed citations
13.
Sng, Christopher C.T., Sarah Benafif, Neha Chopra, et al.. (2020). 1704P COVID-19 mortality in patients receiving anti-cancer therapy in a UK national cancer centre. Annals of Oncology. 31. S1004–S1004. 1 indexed citations
14.
Leongamornlert, Daniel, Edward J. Saunders, Sarah Wakerell, et al.. (2019). Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. European Urology. 76(3). 329–337. 36 indexed citations
15.
Krell, Daniel, et al.. (2017). Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer. International Journal of Gynecological Cancer. 27(6). 1118–1122. 5 indexed citations
16.
Benafif, Sarah & Rosalind A. Eeles. (2016). Diagnosis and Management of Hereditary Carcinoids. Recent results in cancer research. 205. 149–168. 4 indexed citations
17.
Benafif, Sarah & Rosalind A. Eeles. (2016). Genetic predisposition to prostate cancer. British Medical Bulletin. 120(1). 75–89. 32 indexed citations
18.
Lamarca, Ángela, Sarah Benafif, Paul J. Ross, John Bridgewater, & Juan W. Valle. (2015). Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. European Journal of Cancer. 51(13). 1694–1703. 24 indexed citations
19.
Hall, Marcia & Sarah Benafif. (2015). An update on PARP inhibitors for the treatment of cancer. OncoTargets and Therapy. 8. 519–519. 90 indexed citations
20.
Lamarca, Ángela, Sarah Benafif, John Bridgewater, Paul J. Ross, & Juan W. Valle. (2014). Efficacy and safety of cisplatin and gemcitabine (CG) chemotherapy for advanced biliary tract cancer (ABC) in jaundiced patients (pts).. Journal of Clinical Oncology. 32(3_suppl). 294–294. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deniz Yamaç Breakdown of academic impact, for papers by C Singer Breakdown of academic impact, for papers by Pedro Exman Breakdown of academic impact, for papers by Erika Matos Breakdown of academic impact, for papers by Kenji Higaki Breakdown of academic impact, for papers by Valentina Sini Breakdown of academic impact, for papers by Carolyn Cullinane Breakdown of academic impact, for papers by Ryan Geschwindt Breakdown of academic impact, for papers by James P. De Andrade Breakdown of academic impact, for papers by Zhi‐Gang Sun
Rankless by CCL
2026